middle.news
Arovella begins human testing of off-the-shelf ALA-101 therapy
8:41am on Tuesday 27th of October, 2026 AEDT
•
Biotechnology
Read Story
Arovella begins human testing of off-the-shelf ALA-101 therapy
8:41am on Tuesday 27th of October, 2026 AEDT
Key Points
First patient dosed at The Alfred in phase 1 SAPPHIRE trial
ALA-101 targets relapsed or refractory CD19-positive blood cancers
Open-label study will assess safety, pharmacology and preliminary efficacy
Adaptive dose escalation and expansion design
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE